Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Clinical trial NCT02032823 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02032823
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-22
- Primary completion
- 2020-03-27
- Enrollment
- 1837
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.